Thalidomide treatment of resistant or relapsed multiple myeloma patients.

Background And Objectives: Thalidomide is currently used as a very promising drug in patients with recurrent multiple myeloma or those refractory to chemotherapy. Literature data show prolonged survival in patients with advanced multiple myeloma treated with thalidomide but the optimal time and dose of thalidomide treatment remain to be established.

Design And Methods: We have treated 53 refractory or relapsed myeloma patients with thalidomide (Grunenthal, Aachen).